RXO (RXO) Reports In-Line Q4 EPS; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures outperform after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
RXO, Inc. (RXO) PT Lowered to $24 at Barclays
February 5, 2025 2:17 PM ESTBarclays analyst Brandon Oglenski lowered the price target on RXO, Inc. (NYSE: RXO) to $24.00 (from $30.00) while maintaining a Overweight rating.
The analyst comments "4Q EBITDA slightly ahead of consensus despite elevated costs. RXO reported 4Q24 adjusted EPS of 6c, ahead of... More
